Abstract
Low molecular weight heparin has been extensively evaluated for the prevention of preeclampsia in high-risk pregnant women; however, the results from these trials have been conflicting. This review discusses the potential mechanisms of action of low molecular weight heparin for the prevention of severe preeclampsia, how to optimize the selection of high-risk women for participation in future trials, and the importance of trial standardization.
Author supplied keywords
Cite
CITATION STYLE
McLaughlin, K., Scholten, R. R., Parker, J. D., Ferrazzi, E., & Kingdom, J. C. P. (2018, April 1). Low molecular weight heparin for the prevention of severe preeclampsia: where next? British Journal of Clinical Pharmacology. Blackwell Publishing Ltd. https://doi.org/10.1111/bcp.13483
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.